Immune checkpoint inhibitors (ICIs) such as anti-programmed cell death receptor-1 (PD-1) and/or programmed cell death ligand-1 (PD-L1) therapeutic monoclonal antibodies reinvigorate the anti-tumor immunological activities by reversing immune checkpoint receptor-induced immunosuppressive effects [1,2,3,4]. Here, CD274 is linked to neoplasm.